Filing Flows › 4D Molecular Therapeutics (FDMT) › R&D spending
4D Molecular Therapeutics (FDMT) R&D spending by quarter
4D Molecular Therapeutics' R&D spending was $68.3M in Q2 2026 (second quarter 2026), +5% from Q1 2026. Over the last 7 quarters it ranged from $40.7M (Q1 2025) to $68.3M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $68.3M | +5% | +42% |
| Q1 2026 | $65.0M | +13% | +60% |
| Q4 2025 | $57.6M | +17% | +34% |
| Q3 2025 | $49.4M | +3% | — |
| Q2 2025 | $48.0M | +18% | — |
| Q1 2025 | $40.7M | -6% | — |
| Q4 2024 | $43.1M | — | — |
Q2 2026 at a glance
4D Molecular Therapeutics, Q2 2026: revenue $3.8M (252× year over year), net loss $72.9M, operating cash flow −$70.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is 4D Molecular Therapeutics' R&D spending?
4D Molecular Therapeutics' R&D spending was $68.3M in Q2 2026 (second quarter 2026), +5% from Q1 2026.
How has 4D Molecular Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $40.7M (Q1 2025) to $68.3M (Q2 2026).
Q2 2026 results → · How 4D Molecular Therapeutics makes money →